Sino Biopharmaceutical Ltd (HK:1177)

:1177

1177

Sino Biopharmaceutical

RESEARCH TOOLSreports

Sino Biopharmaceutical (1177) Stock Forecast & Price Target

Compare

24 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1177 Analyst Ratings

Moderate Buy

2 Buy

1 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Sino

Biopharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1177 Stock 12 Month Forecast

Average Price Target

HK$8.46

▲(43.37% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Sino Biopharmaceutical in the last 3 months. The average price target is HK$8.46 with a high forecast of HK$8.91 and a low forecast of HK$7.91. The average price target represents a 43.37% change from the last price of HK$5.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"HK$2","9":"HK$9","3.75":"HK$3.75","5.5":"HK$5.5","7.25":"HK$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.908155864597695,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$8.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.4589778736,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$8.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.907239475317056,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$7.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,3.75,5.5,7.25,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.29,6.4913966049690535,6.692793209938107,6.89418981490716,7.095586419876214,7.296983024845267,7.4983796298143215,7.699776234783375,7.901172839752428,8.102569444721482,8.303966049690535,8.505362654659589,8.706759259628642,{"y":8.908155864597695,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.29,6.4568444518153845,6.623688903630769,6.790533355446154,6.957377807261539,7.124222259076923,7.2910667108923075,7.457911162707692,7.624755614523077,7.791600066338462,7.958444518153846,8.125288969969231,8.292133421784616,{"y":8.4589778736,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.29,6.414403036562851,6.538806073125701,6.663209109688552,6.787612146251401,6.912015182814252,7.0364182193771025,7.160821255939953,7.285224292502804,7.409627329065653,7.534030365628505,7.6584334021913545,7.782836438754205,{"y":7.907239475317056,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.481,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.481,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.245,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.176,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.807,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.339,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.226,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.272,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.18,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$8.91

Average Price TargetHK$8.46

Lowest Price TargetHK$7.91

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rebecca Liang

Bernstein

HK$7.9

Hold

33.90%

Upside

Reiterated

02/09/26

Bernstein Remains a Hold on Sino Biopharmaceutical (SBMFF)

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$8.5

Buy

44.07%

Upside

Reiterated

01/31/26

BOCOM International Holdings Company Sticks to Its Buy Rating for Sino Biopharmaceutical (SBMFF)

Unknown Analyst

CICC

Not Ranked

CICC

HK$8.9

Buy

50.85%

Upside

Reiterated

01/14/26

CICC Reaffirms Their Buy Rating on Sino Biopharmaceutical (SBMFF)

Unknown Analyst

Daiwa

Not Ranked

Daiwa

HK$10

Buy

69.49%

Upside

Reiterated

11/12/25

Unknown Analyst

GF Securities

Not Ranked

GF Securities

HK$11.54

Buy

95.59%

Upside

Reiterated

10/14/25

Jill Wu

CMB International Securities

HK$9.4

Buy

59.32%

Upside

Reiterated

10/13/25

Linda Shu

HSBC

HK$9.6

Buy

62.71%

Upside

Reiterated

09/30/25

Anita Wei

UBS

HK$12.2

Buy

106.78%

Upside

Reiterated

09/29/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from UBS

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$10

Buy

69.49%

Upside

Reiterated

09/29/25

Unknown Analyst

Sinolink Securities

Not Ranked

Sinolink Securities

HK$11.25

Buy

90.68%

Upside

Reiterated

09/23/25

Tony Ren

Macquarie

HK$7→HK$9.8

Buy

66.10%

Upside

Reiterated

09/08/25

Sino Biopharmaceutical (SBMFF) Gets a Buy from Macquarie

Unknown Analyst

First Shanghai Securities

Not Ranked

First Shanghai Securities

HK$9.7

Buy

64.41%

Upside

Reiterated

08/27/25

Unknown Analyst

China Merchants Securities

Not Ranked

China Merchants Securities

HK$9.8

Buy

66.10%

Upside

Reiterated

08/22/25

Jialin Zhang

Nomura

HK$7.69→HK$9.17

Buy

55.42%

Upside

Reiterated

08/19/25

Nomura Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)

John Yung

Citi

HK$8.8→HK$10.8

Buy

83.05%

Upside

Reiterated

08/19/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from Citi

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rebecca Liang

Bernstein

HK$7.9

Hold

33.90%

Upside

Reiterated

02/09/26

Bernstein Remains a Hold on Sino Biopharmaceutical (SBMFF)

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$8.5

Buy

44.07%

Upside

Reiterated

01/31/26

BOCOM International Holdings Company Sticks to Its Buy Rating for Sino Biopharmaceutical (SBMFF)

Unknown Analyst

CICC

Not Ranked

CICC

HK$8.9

Buy

50.85%

Upside

Reiterated

01/14/26

CICC Reaffirms Their Buy Rating on Sino Biopharmaceutical (SBMFF)

Unknown Analyst

Daiwa

Not Ranked

Daiwa

HK$10

Buy

69.49%

Upside

Reiterated

11/12/25

Unknown Analyst

GF Securities

Not Ranked

GF Securities

HK$11.54

Buy

95.59%

Upside

Reiterated

10/14/25

Jill Wu

CMB International Securities

HK$9.4

Buy

59.32%

Upside

Reiterated

10/13/25

Linda Shu

HSBC

HK$9.6

Buy

62.71%

Upside

Reiterated

09/30/25

Anita Wei

UBS

HK$12.2

Buy

106.78%

Upside

Reiterated

09/29/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from UBS

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$10

Buy

69.49%

Upside

Reiterated

09/29/25

Unknown Analyst

Sinolink Securities

Not Ranked

Sinolink Securities

HK$11.25

Buy

90.68%

Upside

Reiterated

09/23/25

Tony Ren

Macquarie

HK$7→HK$9.8

Buy

66.10%

Upside

Reiterated

09/08/25

Sino Biopharmaceutical (SBMFF) Gets a Buy from Macquarie

Unknown Analyst

First Shanghai Securities

Not Ranked

First Shanghai Securities

HK$9.7

Buy

64.41%

Upside

Reiterated

08/27/25

Unknown Analyst

China Merchants Securities

Not Ranked

China Merchants Securities

HK$9.8

Buy

66.10%

Upside

Reiterated

08/22/25

Jialin Zhang

Nomura

HK$7.69→HK$9.17

Buy

55.42%

Upside

Reiterated

08/19/25

Nomura Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)

John Yung

Citi

HK$8.8→HK$10.8

Buy

83.05%

Upside

Reiterated

08/19/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from Citi

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sino Biopharmaceutical

3 Months

xxx

Success Rate

3/3 ratings generated profit

Average Return

+46.57%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +46.57% per trade.

1 Year

Ziyi ChenGoldman Sachs

Success Rate

2/2 ratings generated profit

Average Return

+15.50%

reiterated a buy rating 9 months ago

Copying Ziyi Chen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.50% per trade.

2 Years

xxx

Success Rate

2/3 ratings generated profit

Average Return

+22.23%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +22.23% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1177 Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1177 has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 1177 average Analyst price target in the past 3 months is 8.46.

Each month's total comprises the sum of three months' worth of ratings.

1177 Financial Forecast

1177 Earnings Forecast

Currently, no earnings data available.

1177 Sales Forecast

Currently, no sales data available.

1177 Stock Forecast FAQ

What is HK:1177’s average 12-month price target, according to analysts?

Based on analyst ratings, Sino Biopharmaceutical Ltd’s 12-month average price target is 8.46.

What is HK:1177’s upside potential, based on the analysts’ average price target?

Sino Biopharmaceutical Ltd has 43.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sino Biopharmaceutical Ltd a Buy, Sell or Hold?

Sino Biopharmaceutical Ltd has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.

What is Sino Biopharmaceutical Ltd’s share price target?

The average share price target for Sino Biopharmaceutical Ltd is 8.46. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$8.91 ,and the lowest forecast is HK$7.91. The average share price target represents 43.37% Increase from the current price of HK$5.9.

What do analysts say about Sino Biopharmaceutical Ltd?

Sino Biopharmaceutical Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Sino Biopharmaceutical Ltd?

To buy shares of HK:1177, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Sino Biopharmaceutical (1177) Stock Forecast & Price Target

1177 Analyst Ratings

1177 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sino Biopharmaceutical

1177 Analyst Recommendation Trends

1177 Financial Forecast

1177 Earnings Forecast

1177 Sales Forecast

1177 Stock Forecast FAQ

Detailed List of Analyst Forecasts